Skip to content

Startup & venture capital news

T-Therapeutics raises USD 133m for clinical programmes

Advent Life Sciences and British Business Bank co lead the Series B

By /

LinkedInX
T-Therapeutics: T-Therapeutics raises USD 133m for clinical programmes

T-Therapeutics announced an oversubscribed USD 133 million Series B to move two T cell receptor programmes into clinical development. Advent Life Sciences and British Business Bank co led the financing, with Johnson and Johnson Innovation, Samsara BioCapital, M Ventures, Lilly and existing shareholders participating. The Cambridge biotechnology company uses its OpTiMus platform to identify fully human receptors for targets inside cells. Chief executive Theodora Harold says the funding supports oncology and autoimmune programmes through clinical proof of concept. The company also appointed Kirsty Crame as chief development officer. Therapeutic potential described in the announcement remains preclinical and should not be read as evidence of patient benefit.

Keep reading

More Funding

All stories